Saturday 17 October 2026 Export KYNB’s income statement to Excel — free account

Kyntra Bio Inc

In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.85 0.51 −9.51%

Follow KYNB

Alert me

Market cap: $21.7M
P/E: 0.1×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 5/9
Altman Z: −20.33
Beneish M: −4.57
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	1	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.11%

Capital & Financial Ratios $m

Market Cap 21.70

Revenue 4.62

Net Income 183.19

Free Cash Flow (38.05)

Net Debt (91.32)

Current Ratio 2.69

Debt/Equity 0.00

P/E ratio 0.11

Fwd P/E (0.48)

P/S ratio 4.25

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (119.09%)

Next Y EPS Growth (13.78%)

Next Y revenue growth (0.26%)

Next 5Y EPS Growth 3.89%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.38%

10-year low 10-year high

EV/Sales against its own 10 years 70.17%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	203	50	89	91
Receivables	5	0	0	0
Inventory	17	3	4	3
Other	66	111	—	—
	332	197	99	97

	2023	2024	2025	Q'26
Payables	16	5	4	8
ST’ Debt	—	—	—	—
Other	44	39	—	—
	218	133	29	36

Compound Annual Growth %

	10y	5y	3y
Sales	(28.36%)	(48.42%)	(64.23%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4	(1)	—	—	—
’25	3	1	1	1	6
’24	25	1	0	3	30
’23	36	44	40	—	47
’22	61	30	16	34	141
’21	38	24	156	17	235
’20	24	43	44	65	176

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	(4)	—	—	—
’25	3	13	(2)	(18)	(5)
’24	(59)	(40)	(8)	(30)	(138)
’23	(102)	(111)	(85)	(18)	(315)
’22	(8)	(33)	(52)	(53)	(146)
’21	(45)	(27)	44	(55)	(82)
’20	(59)	150	(1)	(7)	82

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(14)	(4)	—	—	—
’25	3	13	(2)	(18)	(5)
’24	(59)	(40)	(8)	(30)	(137)
’23	(102)	(112)	(85)	(19)	(318)
’22	(45)	(34)	(53)	(53)	(185)
’21	(46)	(28)	18	(56)	(112)
’20	(60)	149	(2)	(10)	78

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.76)	2.96	—	—	—
’25	1.25	(1.88)	49.61	(3.51)	45.37
’24	(8.25)	(4.00)	(4.25)	4.50	(12.00)
’23	(20.25)	(22.50)	(16.25)	(14.25)	(73.00)
’22	(17.00)	(19.50)	(24.50)	(17.50)	(78.50)
’21	(19.50)	(36.25)	13.50	(36.25)	(78.50)
’20	(22.25)	(23.75)	8.75	(16.00)	(52.75)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	359.50	523.75	931.75	808.30	566.25	247.00	195.25	8.33	4.50	4.85	Analyst estimates 2026–2028 Powerpack
	High	797.50	1,503.75	1,713.75	1,530.75	1,289.00	1,430.23	457.75	642.25	73.25	21.95
People
People	Employees	364	423	461	531	599	566	592	486	225	34
	Revenue/emp, $m	0.50	0.31	0.46	0.48	0.29	0.42	0.24	0.10	0.13	0.19
Income, $m
Income, $m	Revenue	183	131	213	257	176	235	141	47	30	6
	Gross margin, %	100.00	100.00	100.00	99.55	94.97	94.53	85.59	91.53	47.47	91.37
	EBT	(58)	(121)	(86)	(77)	(189)	(291)	(295)	(323)	(153)	(58)
	EBT margin, %	(31.74)	(92.03)	(40.44)	(29.87)	(107.04)	(123.53)	(209.52)	(690.60)	(517.76)	(905.19)
	Net income	(58)	(121)	(86)	(77)	(189)	(290)	(294)	(284)	(48)	183
	Depreciation	9	8	7	18	22	17	12	5	1	1
Per share, $
Per share, $	Revenue	72.99	44.87	63.33	74.04	49.06	63.70	37.60	12.03	7.40	1.59
	Earnings	(24.50)	(43.25)	(25.75)	(22.25)	(52.75)	(78.50)	(78.50)	(73.00)	(12.00)	45.37
	Cash flow	2.83	(22.78)	(22.65)	(22.71)	22.70	(22.26)	(38.99)	(80.94)	(34.48)	(1.18)
	Capex	(0.50)	(2.91)	(2.33)	(1.66)	(1.11)	(8.17)	(10.35)	(0.65)	0.19	(0.01)
	Free cash flow	2.33	(25.69)	(24.98)	(24.37)	21.59	(30.43)	(49.33)	(81.59)	(34.29)	(1.19)
	Book value	69.77	187.61	157.17	154.50	122.82	62.02	(0.40)	(47.19)	(51.25)	(4.21)
	Shares, m	3	3	3	3	4	4	4	4	4	4
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19
	P/S	7.30	28.25	18.27	14.48	18.90	5.53	10.61	1.73	1.79	5.51
	P/B	7.63	6.76	7.36	6.94	7.55	5.68	0.00	0.00	0.00	0.00
	EV/Sales	6.44	23.38	15.81	12.60	15.23	4.31	8.37	(0.83)	2.95	14.55
	EV/FCF	201.61	(40.83)	(40.08)	(38.28)	34.60	(9.02)	(6.38)	0.12	(0.64)	(19.47)
Cash, $m
Cash, $m	Operating cash flow	7	(67)	(76)	(79)	82	(82)	(146)	(315)	(138)	(5)
	Capex	(1)	(8)	(8)	(6)	(4)	(30)	(39)	(3)	1	0
	Free cash flow	6	(75)	(84)	(84)	78	(112)	(185)	(318)	(137)	(5)
Balance, $m
Balance, $m	Working capital	201	663	601	600	592	249	219	114	63	70
	Total debt	97	98	108	38	25	106	97	72	73	—
	Net debt	(156)	(638)	(513)	(496)	(661)	(299)	(325)	(132)	23	(89)
	Shareholders’ equity	175	548	528	535	441	229	(1)	(184)	(205)	(17)
Returns, %
Returns, %	ROA	(12.35)	(17.67)	(9.71)	(8.86)	(22.48)	(36.24)	(42.44)	(55.00)	(14.91)	109.81
	ROIC	(162.20)	0.00	(360.67)	(142.19)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(31.22)	(33.44)	(16.06)	(14.47)	(38.76)	(86.50)	(258.01)	307.01	24.48	(165.18)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CYAD Celyad SA	$23.8M	— (loss-making)	— (loss-making)	—	n/m	+78.72% (above 0%: growing)	0.00%	0.00%	Compare
PLRZ Polyrizon Ltd.	$23.7M	—	—	—	—	−744.51% (below 0%: shrinking)	—	—	Compare
IMMP Prima BioMed Ltd	$23.7M	— (loss-making)	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
EVAX Evaxion A/S - Sponsored ADR	$23.4M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
ESLA Estrella Immunopharma, Inc.	$23.3M	— (loss-making)	—	—	n/m	−329.19% (below 0%: shrinking)	—	0.00%	Compare
CNTX Context Therapeutics Inc.	$22.1M	— (loss-making)	—	—	n/m	−20.61% (below 0%: shrinking)	0.00%	0.00%	Compare
QNTM Quantum Biopharma Ltd.	$21.9M	— (loss-making)	— (loss-making)	—	n/m	+5.88% (above 0%: growing)	0.00%	0.00%	Compare
KYNB Kyntra Bio Inc	$21.7M	0.1×	— (loss-making)	−209.35% (below 0%: shrinking)	n/m	−131.50% (below 0%: shrinking)	100.14%	1,192.27%
COCP Cocrystal Pharma, Inc.	$19.8M	— (loss-making)	— (loss-making)	−81.05% (below 0%: shrinking)	n/m	−16.75% (below 0%: shrinking)	100.00%	(3,032.38%)	Compare
Median of peers	$23.3M	—	—	—	—	−38.65%	50.00%	0.00%

All 614 Biotechnology stocks →

Kyntra Bio Inc (KYNB) key facts

Kyntra Bio Inc (KYNB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KYNB traded at $4.85, a market capitalization of $21.7 million.
Return on equity was −165.2% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −20.33 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.